Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: GBT), in connection with the proposed acquisition of the Company by Pfizer Inc. (NYSE: PFE). Under the terms of the merger agreement, the Company's shareholders will receive $68.50 in cash for each share of Global Blood common stock owned. The transaction is valued at approximately $5.4 billion.
If you own Global Blood shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
https://www.weisslaw.co/news-and-cases/gbt Or please contact:Joshua Rubin, Esq.Weiss Law 305 Broadway, 7th FloorNew York, NY 10007(212) 682-3025(888) firstname.lastname@example.org
Weiss Law is investigating whether (i) Global Blood's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $68.50 per-share merger consideration adequately compensates Global Blood's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. Notably, at least one analyst set a price target for the Company of $100 per share, $31.50 above the per-share merger consideration.
Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at email@example.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-weiss-law-investigates-global-blood-therapeutics-inc-301601690.html
SOURCE Weiss Law